Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaZymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval for two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+).
- Covation Sponsors Family Fun Ride at the 2026 Sun Hung Kai Properties Hong Kong CyclothonCovation Holdings Limited (“Covation” or the “Group”), a world-leading wheeled product innovator and manufacturer, is pleased to announce its sponsorship of the Covation Family Fun Ride at the 2026 Sun Hung Kai Properties Hong Kong Cyclothon. Organized by the Hong Kong Tourism Board (“HKTB”), the flagship international sporting spectacle will take place on 11 October (Sunday), bringing together thousands of cyclists across the city’s iconic bridges and landmarks while showcasing the unique scenery. Mr. Bruno Maier, Co-CEO of Covation, said, “We are proud to support the Hong Kong Cyclothon—a world-class sporting spectacle that showcases the energy and iconic landscape of Hong Kong. As a global force in outdoor adventure, Covation shares the event’s passion for driving health, wellness, and a vibrant cycling culture across the community, as well as its sports for charity spirit. While the Cyclothon brings together elite global competitors and cycling enthusiasts, our sponsorship of the Family Fun Ride allows us to introduce families and young riders to the transformative joy of cycling. Through our century-old children’s bicycle brand, Huffy, we have inspired generations to connect through cycling. We are thrilled to play a meaningful role in this citywide extravaganza, offering families a unique opportunity to create lasting memories together while supporting a charitable cause.” Covation – a name that merges “Collaboration” and “Innovation” — is on a mission to revolutionize how people move, connect, and explore—by developing exceptional products for bold experiences across wheeled categories and beyond. It is a Hong Kong-headquartered vertically integrated holding company, specializing in the research, development, manufacturing, distribution and global operations of cycling and outdoor brands, driven by manufacturing excellence. The Group owns multiple outdoor cycling brands, including Huffy, Batch, and Green Machine. Currently, its business serves millions of consumers across more than 50 countries and regions worldwide. The Covation Family Fun Ride is designed to encourage outdoor recreation and family bonding. Open to participants aged 6 to 70, each entry group consists of one parent paired with one child or youth. In line with the Cyclothon’s sports for charity spirit, registration fees collected from the Covation Family Fun Ride will be donated in full to The Community Chest of Hong Kong to support local underprivileged communities. Beyond the rides, the event will host a dedicated cycling-themed carnival at the West Kowloon Cultural District, featuring a diverse programme of sports, entertainment, family-friendly activities and culinary delights, allowing locals and visitors to fully immerse themselves in the excitement of the cycling extravaganza. Covation will also host a booth at the venue, featuring its exceptional wheeled products and connecting with cycling enthusiasts. This year’s Cyclothon is further enriched new elements, including an upgraded 56km non-competitive ride on a “Five Tunnels, Three Bridges” route that will take riders along roads rarely opened to cyclists. The enhanced route provides an ideal opportunity to explore Hong Kong’s diverse urban landscapes, showcasing the unique blend of old and new districts. This, together with the 32km ride, is expected to see the participation of more than 6,500 cyclists. Covation Family Fun Ride Highlights: Event Date: Sunday, 11 October 2026 Group Format: 1 Parent + 1 Child/Youth (6–70 years old) Entry Fee: HK$100 per group (100% donated to charity) Public Registration: Registration is now open via the event website Photo: Bruno Maier (row 2, 3rd from right), Covation Co-CEO, joins Hong Kong Tourism Board officials and event partners at the launch press conference of the 2026 Sun Hung Kai Properties Hong Kong Cyclothon. About Covation Holdings Limited Covation Holdings Limited (“Covation”) is a vertically integrated holding company headquartered in Hong Kong, specializing in the research, development, manufacturing, distribution and global operations of cycling and outdoor brands, as well as excellence in manufacturing. As a world-leading manufacturer and assembler of bicycles and components, the company operates modern smart manufacturing facilities in China, Cambodia and Vietnam. Leveraging its vertically integrated supply chain advantages and rigorous quality control system, Covation has established an efficient operational network with strategic branches across the United States, Mexico, Canada, the United Kingdom, European Union, Hong Kong, and China, consistently delivering exceptional products to global customers. Covation’s portfolio encompasses internationally renowned outdoor sports brands, including Huffy, Batch, and Green Machine. The company maintains extensive licensing partnerships with world-class partners such as Disney, Marvel, Lucasfilm, Universal Studios, Paramount, Microsoft, and Sanrio.
- PLT Health SolutionsPLT Health Solutions Brings Its Clinically Supported Branded Ingredient Platform to Vitafoods AsiaFirst-Time Exhibitor Will Showcase 30+ Ingredients Across Joint Health, Healthy Aging, Sports Nutrition, Energy, Sleep/Stress and Cognitive Health, Including the Asia Debut of the Next-Generation Kinexa Joint Longevity Complex MORRISTOWN, N.J., Aug. 25, 2026 -- PLT Health...
- TruvantTruvant Acquires New Jersey-Based Multi-Pak Packaging, a Specialist in Vitamins, Supplements and OTCAcquisition adds specialist nutritional supplement, OTC, consumer health and beauty packaging capabilities as well as deepens Truvant's support for health, wellness and beauty brands. — Truvant, a pure-play contract packaging and...
- Cellenkos, Inc.Cellenkos Receives FDA Fast Track Designation for CK0803 in Amyotrophic Lateral Sclerosis (ALS)The FDA has granted Fast Track designation to CK0803 for ALS, an investigational therapy that showed an approximately 60% decrease in neurofilament light chain and a 200% increase in plasma IL-10 levels during initial clinical evaluations. Cord blood-derived, CNS-homing T-regulatory cell...
- Hyland's Consumer HealthTobe Cohen Named Chief Executive Officer of Hyland’s Consumer Health and Hello Bello Consumer WellnessLOS ANGELES, August 25, 2026--Hyland’s Consumer Health ("Hyland’s"), a leading pediatric-focused consumer health and wellness company that comprises the Hyland’s Naturals and Hello Bello brands, today announced that it has appointed Tobe Cohen as Chief Executive Officer. He succeeds Will Righeimer who will remain involved with Hyland’s as an Executive Advisor and Board member.
- Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business UpdateClinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs
- Avetta Cultural Maturity Index Named a 2026 New Product of the Year by Occupational Health & SafetyLEHI, Utah & HOUSTON, August 25, 2026--Avetta®, the leader in intelligent work readiness across global supply chains, today accepted a 2026 New Product of the Year honor from Occupational Health & Safety (OH&S) in the EHS Software category for the Avetta Cultural Maturity Index (CMI). The award highlights Avetta’s continued investment in raising the standard for supply chain safety by bringing together AI-powered technology, human expertise and industry collaboration to help organizations antici
- McKesson CorporationMcKesson Signs Agreement to Acquire Precision Medicine Group, LLCCompanies: McKesson CorporationIRVING, Texas, August 25, 2026--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC ("Precision Medicine Group"), a global provider of clinical research and biopharma commercialization services.
- Septerna, Inc.Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical OfficerSepterna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.
- Rhelion Life Sciences Corp.Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and DepressionFilament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in people living with metastatic solid tumors or incurable hematologic malignancies.Toronto, Ontario--(August 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within...
- AI-Driven Bioprinting Emerges as a High-Conviction Investment Theme as Corporate AI Spending Surpasses $252 Billion“AI can make bioprinting more precise, predictive and personalized, accelerating its path from research to clinical use.”